原料辞典検索/polyglyceryl-3-methylglucose-distearate/POLYGLYCERYL-3 METHYLGLUCOSE DISTEARATE
Tier 1 Monograph · SSOT 15 FieldsRaw .md (GEO) ↗
合成 (Synthetic)

POLYGLYCERYL-3 METHYLGLUCOSE DISTEARATE

標準 INCI 準拠: POLYGLYCERYL-3 METHYLGLUCOSE DISTEARATE
乳化剤
[EU CosIng Official Definition] Methyl-D-glucopyranoside, ethers with 1,2,3-propanetriol homopolymer, octadecanoates (1:1:2) (3 mol glycerol average molar ratio)
結論先行 エグゼクティブ規制・安全性ファクトボックスAEO / GEO CITATION ANCHOR

化粧品における POLYGLYCERYL-3 METHYLGLUCOSE DISTEARATE のグローバル配合基準と処方特性とは?

POLYGLYCERYL-3 METHYLGLUCOSE DISTEARATE(CAS番号: N/A)は、化粧品処方において主に乳化剤として配合される原料です。日本厚労省/JCIA(規制なし)、韓国MFDS(規制なし)、欧州CosIng(規制なし)など6大法域の法定基準下で管理され、通常 1–4%(適正安定域 pH 4.5–8.5)で処方されます。

7大トラック 国別・用途別 公式全成分表示名称マトリクス

各国公的告示原典のみ収録 · 機械翻訳・任意音訳ゼロ
7-Track Official Statutory Label Names for POLYGLYCERYL-3 METHYLGLUCOSE DISTEARATE
法域・規制トラック公式全成分表示名称ワンクリックコピー
① 韓国 (MFDS 化粧品標準名称)POLYGLYCERYL-3 METHYLGLUCOSE DISTEARATE (KR MFDS Registered)
② 韓国旧名称履歴 (301 リダイレクト)Former KR Nomenclature Redirect Active—
③ 欧州連合 (EU CosIng EC 1223/2009)POLYGLYCERYL-3 METHYLGLUCOSE DISTEARATE
④ 米国一般化粧品 (US PCPC / MoCRA INCI)POLYGLYCERYL-3 METHYLGLUCOSE DISTEARATE
⑤ 米国 FDA OTC モノグラフ有効成分名— (米国 OTC 対象外 / 一般化粧品原料)—
⑥ 中国 (NMPA IECIC 標準中国語名称)聚甘油-3 甲基葡糖二硬脂酸酯
⑦ 日本化粧品表示名称 / 医薬部外品外原規名称 (JCIA / MHLW)POLYGLYCERYL-3 METHYLGLUCOSE DISTEARATE (標準INCI参照 · 任意カタカナ音訳排除)

Layer 1 — 6大法域 法定配合上限および規制ステータス

Layer 1 Statutory Regulatory Limits Across 6 Regions for POLYGLYCERYL-3 METHYLGLUCOSE DISTEARATE
法域規制ステータス配合上限制限条件および一次法源出典
韓国 (MFDS)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
欧州 (EU)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
米国 (FDA)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
中国 (NMPA)配合可能GMPIECIC Entry #3830
日本 (MHLW)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
ASEAN (ACD)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)

Layer 2 — 毒性・安全性評価上限 (US CIR / EU SCCS / CN IECIC)

「欧州 SCCS 安全性評価上限」は消費者安全科学委員会が安全域 (MoS≥100) と判定した毒性学的上限であり、「米国 CIR 市販製品最大報告濃度」および「中国 IECIC 最高歴史使用量」は市販製品における最大実績濃度です。

Layer 2 Toxicological & Historical Safe Use Concentrations for POLYGLYCERYL-3 METHYLGLUCOSE DISTEARATE
安全性評価基準適用範囲・用途安全濃度範囲判定結果および文献参照
中国 IECIC 最高歴史使用量leave_on≤ 6%安全判定 (MoS≥100)NMPA IECIC (2025) Entry 03628 (2025)
中国 IECIC 最高歴史使用量rinse_off≤ 5%安全判定 (MoS≥100)NMPA IECIC (2025) Entry 03628 (2025)
⚠️ 参考用案内 (免責事項): 本辞典の成分名・規制上限・処方ガイドは研究開発の参考用です。法改正の時差やデータの誤記・漏れがあり得るため、実際の処方・ラベル表示・届出前には必ず管轄当局の最新告示原文をご確認ください。本情報の利用により生じた問題について運営主体は法的責任を負いません。
Interactive Quartile Box-Plot (Min–Q1–Median–Q3–Max)

Layer 3 Formulation Concentration Box-Plot vs. Statutory Limit

Emulsion / Creamn=195
Min 1% · Q1 1.8% · Median 2.5% · Q3 3% · Max 4%
Sunscreen / Colorn=48
Min 1% · Q1 1.5% · Median 2% · Q3 3% · Max 4%
Emulsion / Cream — PEG-free O/W primary lamellar emulsifier
Verified Source: Evonik TEGO Care 450 TDS & Formulation Library (n=195) (cir_safety) · Evonik 178 · SEPPIC 17
Typical Median: 2.5%

Layer 3 — 剤形別通常配合濃度 (四分位数 n≥5) & 物理化学・相溶性ガイド

Layer 3 Formulation Concentration Quartiles by Product Category for POLYGLYCERYL-3 METHYLGLUCOSE DISTEARATE
剤形グループMin – Q1 – Median – Q3 – Max (%)処方役割・作用機序Source ID
剤形群 B — 乳液・エマルジョン・クリーム1% · 1.8% · 2.5% · 3% · 4%PEG-free O/W primary lamellar emulsifierEvonik TEGO Care 450 TDS & Formulation Library (n=195)
剤形群 D — 日焼け止め (UV)・メイクアップ・ファンデーション1% · 1.5% · 2% · 3% · 4%O/W sunscreen & tone-up cream emulsifierEvonik TEGO Care 450 Sunscreen Guide
Cutaneous Permeation Science (500 Dalton Rule)MW: Macro/Complex · LogP: N/A

Stratum Corneum Penetration Depth & Bio-Spicule Transdermal Delivery

Stratum Corneum (Brick & Mortar Barrier · 10–20 µm)500 Da Molecular Weight Cutoff BarrierViable Epidermis (Keratinocytes & Melanocytes · 50–100 µm)Target for Brightening (Tyrosinase/Melanosome) & Barrier LipidsPapillary Dermis (Fibroblasts & ECM Collagen · 150–300 µm)Target for Collagen I/III Synthesis, Peptides, PDRN & ExosomesEpidermal Passive Permeation (<500 Da)
Molecular Weight & LogP Permeation Diagnosis
Low Molecular Weight (320 Da ≤ 500 Da) — Passive Permeation Feasible

Under passive topical application, molecules diffuse tortuously through intercellular lipids. Hydrophilic compounds >500 Da remain primarily on the outer stratum corneum.

Estimated Target Depth
40–90 µm
Optimal Delivery System
Polyol Enhancer / Serum
Colloid Interface, pH Spectrum & Thermal Stability

pH Stability Window (0–14), Thermal Limit & HLB Colloidal Phase Behavior

Oil soluble (melts at ~55~60°C)
Optimal Formulation pH Stability Window (0–14)pH 4.5 – 8.5
0245.5791114

Outside pH 4.5–8.5, risk of hydrolysis, viscosity loss, or ionic dissociation increases.

Maximum Thermal Processing Limit (°C)≤ 85°C
25°C45°C60°C75°C85°C100°C

Thermally stable up to 85°C during standard emulsification.

HLB Scale (0–20) & Colloidal Micelle / Lamellar Phase Simulator
O/W Oil-in-Water Micelle Emulsion (Lotion / Cream)
HLB 12.0
W/O (3–6)Lamellar (8–10.5)O/W Emulsion (11–15)Solubilizer (15–19)O/W Droplet
Biochemical Signaling & Mechanism Pathway

Cellular & Molecular Target Mechanism Flow

1. Epidermal Interaction→ Upregulation / Activation
Intercellular Lipid & Hydration Matrix
→
TEWL Reduction & Barrier Conditioning
2. Homeostasis Modulation⊣ Inhibition / Blockade
Oxidative Stress (ROS) & Irritant Cascade
⊣
Cutaneous Soothing & Homeostasis
Formulation Ontology Radial Graph

Interactive Synergy Pairings (Solid) & Incompatibility Warnings (Dashed)

+ CETEARYL ALCOHOL+ GLYCERYL STEARATE+ SODIUM STEAROYL GL…+ CAPRYLIC/CAPRIC TR…✕ Emulsification below…POLYGLYCERYL-3 MET…
Interactive Node Guide

Click any green synergy node to jump directly to its monograph, or click a red dashed node to inspect the chemical incompatibility mechanism.

代表商品名参考 (商標法第90条第1項第2号 記述的表示)
TEGO® Care 450

商品名は研究者がグレードを識別するための参考表記であり、各商標権は原メーカーに帰属します。

学術・毒性・処方統合モノグラフ

Tier 1 Synthesis

本原料に紐づく NIH PubMed 査読付き論文アブストラクトおよび公的毒性評価報告書のみに基づいて作成された学術要約です。

■ [1. Chemical Identity & International Labeling Nomenclature] - INCI Name: POLYGLYCERYL-3 METHYLGLUCOSE DISTEARATE | CAS No.: N/A | EC No.: N/A - Origin: SYNTHETIC | Functions: - Physicochemical Profile: Formula | MW /(Polymer/Complex) | / | Ionic Nature: non-ionic | CosIng/MFDS - Official Regional Label Names: US [POLYGLYCERYL-3 METHYLGLUCOSE DISTEARATE] · EU [POLYGLYCERYL-3 METHYLGLUCOSE DISTEARATE] · CN [聚甘油-3 甲基葡糖二硬脂酸酯] · JP [-] · JP Quasi-Drug [-] ■ [2. Dermatological Mechanism of Action & Functional Role] - Methyl-D-glucopyranoside, ethers with 1,2,3-propanetriol homopolymer, octadecanoates (1:1:2) (3 mol glycerol average molar ratio) Classified under origin 'synthetic', it acts within the cosmetic vehicle or stratum corneum to deliver performance and structural formulation stability. ■ [3. Global 6-Jurisdiction Regulatory Status & Safety Limits (Layer 1 & Layer 2)] - Regional Summary: KR: NONE | EU: NONE | US: NONE | CN: ALLOWED | JP: NONE | ASEAN: NONE (CN IECIC (2025) Entry No. 3830 (聚甘油-3 甲基葡糖二硬脂酸酯)) - No specific Annex prohibition or numeric restriction across the 6 major jurisdictions (Permitted under general GMP safety assessment). - Official Safety & Historical Use Concentration (Layer 2): CN_IECIC_2025 (cn_iecic_max, leave_on): Max 6.0% / CN_IECIC_2025 (cn_iecic_max, rinse_off): Max 5.0% ■ [4. Formulation Dosage Guide by Product Category (Layer 3-A)] - [emulsion_cream] Typical range: 1.0 ~ 4.0% (Median 2.5%, Ref: Evonik TEGO Care 450 TDS & Formulation Library (n=195)) — PEG-free O/W primary lamellar emulsifier - [sun_color] Typical range: 1.0 ~ 4.0% (Median 2.0%, Ref: Evonik TEGO Care 450 Sunscreen Guide) — O/W sunscreen & tone-up cream emulsifier ■ [5. Formulation Engineering, Stability & Incompatibility Matrix (Layer 3-B)] - Addition Phase: Oil Phase (Heat to 75~80°C) - Optimal pH Range: pH 4.5 ~ 8.5 | Max Process Temp: Max 85°C | Electrolyte Tolerance: HIGH - Incompatibility / Caution: Emulsification below 70°C may lead to incomplete liquid crystal formation and viscosity drift - Synergy Pairings: CETEARYL ALCOHOL, GLYCERYL STEARATE, SODIUM STEAROYL GLUTAMATE, CAPRYLIC/CAPRIC TRIGLYCERIDE | Reference Trade Names: TEGO® Care 450 ■ [6. Peer-Reviewed Literature & Official Compendia Evidence] - PMID 29105631 (2017, Pak J Pharm Sci): Phytoformulation of Sassurea lappa plant extract: A Single blind, noninvasive and split face study of cream on various s - PMID 12058808 (2002, Farmaco): Influence of processing conditions in the manufacture of O/W creams: II. Effect on drug availability - PMID 12058807 (2002, Farmaco): Influence of processing conditions in the manufacture of O/W creams: I. Effect on dispersion grade and rheological chara

関連査読付き学術論文 (NIH PubMed) (3)

Phytoformulation of Sassurea lappa plant extract: A Single blind, noninvasive and split face study of cream on various skin parameters [PMID: 29105631 · 2017]
Adnan Q, Akhtar N, Khan BA · Pak J Pharm Sci (2017)

Saussurea lappa (SL) has been reported for its antioxidant and anti-ageing properties. Due to this reason it can be incorporated in a stable phytoformulations for cosmetic use. The objective of the study was to evaluate the anti-aging potential of cosmetic o/w emulsion containing the botanical extract of SL. An emulsion (o/w) was prepared using TEGO&#xae; Care 450 (Polyglceryl-3-Methyl Glucose Distearate) emulsifier and final emulsion was loaded with 4 % extract of SL in aqueous phase. This emulsion evaluated for its antioxidant and anti-ageing properties on healthy human subjects using a non-invasive technique called surface evaluation of living skin (SELS). The formulation containing SL extract showed significant (p&lt;0.05) changes in Skin roughness (SEr) as -3.13%, -6.26%, -9.39%; Skin Scaliness (SEsc) as - 4.19%, -8.39%, -12.58%; Skin wrinkles (SEw) as -0.5%, -1.08%, -1.63%; and Skin smoothness (SEsm) as 3.28%, 6.57%, 9.85%, respectively, after 30, 60 and 90 days of continous use. Topical application of the cosmetic cream containing SL extract exerts have a significant anti-aging effects, perhaps due to the presence of Kaempferol, gallic acid, Caffeic acid and other essential phenolics.

Influence of processing conditions in the manufacture of O/W creams: II. Effect on drug availability [PMID: 12058808 · 2002]
Realdon N, Ragazzi E, Morpurgo M, Ragazzi E · Farmaco (2002)

O/W creams prepared in three mechanical conditions (F with a hand blender; S turbomixer; T vacuum turbo-emulsor) produced different dispersion grades of the internal phase and different rheological characteristics by using surfactants of different chemical nature (polyoxyethylene-cetostearyl alcohols and polyglyceryl-3-methylglucose distearate). Three tests were used (an in vitro release test across a porous membrane; an in vitro simulated absorption test across a porous membrane impregnated with isopropyl myristate; an in vivo absorption test based on the intensity and duration of the erythema produced by methyl nicotinate after application of the cream on the skin) to assess whether the different physical characteristics influence drug availability from the creams. The different physical characteristics due to the mechanical conditions of emulsifying and gelification appeared not to influence drug release and in vivo absorption.

Influence of processing conditions in the manufacture of O/W creams: I. Effect on dispersion grade and rheological characteristics [PMID: 12058807 · 2002]
Realdon N, Perin F, Morpurgo M, Ragazzi E · Farmaco (2002)

Two series of O/W creams having the same general formulation were prepared in three different mechanical conditions (F with an hand blender; S with a turbomixer; T with a vacuum turbo emulsor) using two types of surfactants, polyoxyethylene-cetostearyl alcohols and polyglyceryl-3-methylglucose-distearate. By means of microscopic image analysis it was possible to point out the dispersion grade of the oil internal phase increasing with the energy applied under the conditions of manufacture (F &lt; S &lt; T). The level of dispersion influenced significantly on the rheological characteristics of the creams. With polyoxyethylene-cetostearyl alcohols, the viscosity of creams increased as the energy applied in manufacturing increased, with polyglyceryl-3-methylglucose-distearate on the contrary decreased. Moreover, indifferently to the manufacturing conditions, even in the same concentration of surfactant, the creams obtained with the last produced a much greater viscosity. At a parity of manufacturing conditions the differences between the batches of productions were not significant.

よくある質問 (FAQ)

Q1. POLYGLYCERYL-3 METHYLGLUCOSE DISTEARATE の各国公式全成分表示名称(7トラック)はどのように異なりますか?
日本化粧品工業連合会(JCIA)表示名称は 'POLYGLYCERYL-3 METHYLGLUCOSE DISTEARATE (標準INCI準拠)'、米国PCPC・欧州CosIng INCIは 'POLYGLYCERYL-3 METHYLGLUCOSE DISTEARATE'、中国NMPA IECIC標準中国語名は '聚甘油-3 甲基葡糖二硬脂酸酯' です。
Q2. POLYGLYCERYL-3 METHYLGLUCOSE DISTEARATE のグローバル6大法域における法定配合基準 (Layer 1) は?
6大法域規制ステータス — 日本(JP): none、韓国(KR): none、欧州(EU): none、米国(US): none、中国(CN): allowed、ASEAN: none。
Q3. 処方設計における POLYGLYCERYL-3 METHYLGLUCOSE DISTEARATE の通常配合濃度 (Layer 3) と適正 pH は?
主要剤形 (emulsion_cream) において通常 1〜4%(中央値 2.5%)で配合され、適正pH範囲は 4.5〜8.5 です。
Q4. POLYGLYCERYL-3 METHYLGLUCOSE DISTEARATE の配合禁忌 (Incompatibilities) と推奨シナジー成分は?
推奨シナジーペアは CETEARYL ALCOHOL, GLYCERYL STEARATE, SODIUM STEAROYL GLUTAMATE, CAPRYLIC/CAPRIC TRIGLYCERIDE、配合上の注意点は Emulsification below 70°C may lead to incomplete liquid crystal formation and viscosity drift です。